The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease

  title={The Effect of Mesalamine and Nicotine in the Treatment of Inflammatory Bowel Disease},
  author={Charles R. Bonapace and David A. Mays},
  journal={Annals of Pharmacotherapy},
  pages={907 - 913}
OBJECTIVE: To characterize the usefulness of mesalamine and nicotine in the treatment of active ulcerative colitis and inactive Crohn's disease. DATA SOURCES: Citations were selected from the MEDLINE database. Only those involving human subjects, inflammatory bowel disease, and available in English were selected. STUDY SELECTION: Selection criteria consisted of clinical trials and review articles assessing the effects of mesalamine and nicotine in active ulcerative colitis or inactive Crohn's… 

An investigation into the effect and mechanisms of action of nicotine in inflammatory bowel disease

Nicotine reduced inflammation in the TNBS model of colonic damage confirming the use of nicotine in IBD although the choice of dose requires further investigation.

Hypothesis about mechanisms through which nicotine might exert its effect on the interdependence of inflammation and gut barrier function in ulcerative colitis

A greater understanding of the pharmacodynamics and kinetics of nicotine in relation to the immune system and enhanced knowledge of gut permeability defects in UC are required to establish the exact protective nature of nicotine and its metabolites in UC.

Transport Mechanisms of Nicotine across the Human Intestinal Epithelial Cell Line Caco-2

To characterize the disposition of nicotine in the intestines, intestinal nicotine transport using Caco-2 cells is investigated and specific uptake systems appear to be distinct from organic cation transporters and the transport system for tertiary amines, in terms of its substrate specificity and the pattern of the interaction.

The clinical effectiveness and cost-effectiveness of bupropion and nicotine replacement therapy for smoking cessation: a systematic review and economic evaluation.

Specific interventions included in the review Studies were included if they examined bupropion (150 or 300 mg/day) immediate release and SR formulations, used to aid smoking cessation alone, or as

Involvement of Neuronal Nicotinic Receptors in Disease

Those diseases in which the association is well established are discussed in detail in this chapter and others, in which nAChR involvement is inferred on the basis of indirect evidence, are mentioned in brief.

A tobacco-specific carcinogen, NNK, enhances AOM/DSS-induced colon carcinogenesis in male A/J mice.

It is suggested that smoking increases the risk of inflammation-related colon cancer development and the effects of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone on colon carcinogenesis were examined using an AOM/dextran sulfate sodium (DSS) mouse model.

Neuronal nicotinic receptors: from structure to pathology

Nicotine Evoked Currents in Human Primary Sensory Neurons.



Mesalamine and olsalazine: 5-aminosalicylic acid agents for the treatment of inflammatory bowel disease.

Both rectal mesalamine and oral olsalazine provide clinicians with an effective therapeutic option for the treatment of ulcerative colitis, proctosigmoiditis, and proctitis in patients unresponsive to or intolerant of the effects of sulfasalazine or corticosteroids.

Transdermal nicotine for active ulcerative colitis.

The addition of transdermal nicotine to conventional maintenance therapy improves symptoms in patients with ulcerative colitis.

Transdermal nicotine as maintenance therapy for ulcerative colitis.

Transdermal nicotine alone was no better than placebo in the maintenance of remission of ulcerative colitis, and premature withdrawal due to side effects was more common in the nicotine group.

Mesalamine capsules for treatment of active ulcerative colitis: results of a controlled trial. Pentasa Study Group.

The data suggest that controlled-release mesalamine capsules are a safe and effective monotherapy in doses of 2-4 g daily for treating mild to moderately active ulcerative colitis, as well as for inducing remission, regardless of prior oral steroid or sulfasalazine therapy or extent of disease.

Mesalamine in Crohn's disease with steroid-induced remission: effect on steroid withdrawal and remission maintenance, Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives.

After a prednisolone-induces remission in Crohn's disease, mesalamine facilitates steroid withdrawal and, during the postweaning year, may reduce the relapse rate in certain patient subgroups.

Oral mesalamine (Asacol) for mildly to moderately active ulcerative colitis. A multicenter study.

Colon-targeted oral mesalamine at 2.4 g/d is effective therapy for mildly to moderately active ulcerative colitis and should provide a viable therapeutic alternative to sulfasalazine.